Equity Update - KLBF (3Q26)
November 12, 2026
Kiwoom Research | 9M26 Equity Update - 12 November 2026
PT. Kalbe Farma Tbk. (KLBF)
Resilient Earnings Amid Currency and Cost Pressures
Key Takeaways:
- Growth remains on track. 9M26 revenue grew 11.5% YoY, reaching 75% of our FY26 estimate, while net profit increased 4.0% YoY, achieving 72% of our FY26 forecast.
- Efficiency supports profitability. Lower Opex ratio helped offset rupiah depreciation and higher raw material costs.
- Margin recovery remains key. Focus on lifestyle products, local insulin and GLP-1 production, and selective price increases.
Recommendation: "BUY"
We maintain our “BUY” recommendation on KLBF and raise our target price to IDR1,120 from IDR950, implying a 44.52% upside from the last closing price of IDR775 as of 11 November 2026. Our target price implies a 2027F P/E of 12.5x and P/BV of 1.8x, with projected ROE of 14.5% and dividend yield of 4.2%. Downside risks include weakening consumer purchasing power, intensifying market competition, and rising raw material and operating costs amid geopolitical pressures and rupiah depreciation.
Abdul Azis Setyo Wibowo
Equity Research
KIWOOM SEKURITAS INDONESIA